This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The race to find and bring vaccines to market to fight Covid was impressive. It’s been almost a year since the first Covid vaccine was authorised for use. Meanwhile, China and Russia have rolled out state-owned vaccines. Pfizer/BioNTech’s vaccine dominates the market. billion in vaccine sales this year.
Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.
The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Moderna ’s investigational mRNA vaccine candidate, mRNA-1345, for respiratory syncytial virus (RSV) in adult patients. The investigational mRNA-1345 vaccine uses the same lipid nanoparticles (LNPs) that are also used in the Moderna Covid-19 vaccines.
The Covid-19 pandemic saw a proliferation in novel vaccine technologies being produced rapidly. With the emergence of vaccines came accusations of technology encroachment amongst biotech companies. 2021 was a year of continued innovation and change in the Biopharmaceutical industry.
As the prophylactic landscape for malaria has changed in recent years with vaccine approvals, major issues still remain with ensuring access in remote communities. However, making sure the vaccine reaches everyone can be challenging due to the storage requirements. The Mosquirix vaccine contains two vials.
After a winter marked by a rise in hospitalisations due to the RSV, the FDA has granted its first approval for an Respiratory Syncytial Virus (RSV) vaccine to GSK’s Arexvy for adults ages 60 years and above. This vaccine specifically prevents RSV-related lower respiratory tract disease (LRTD).
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. In the case of most mRNA vaccines, a lipid nanoparticle-based approach was chosen due to its ability to protect the mRNA in the body and prevent degradation.
million government grant from the Flanders Innovation & Entrepreneurship (VLAIO) agency that will be used to fuel the company’s vaccine platform, per a 30 May announcement. The company’s prophylactic yellow fever vaccine is part of its plasmid-launched live attenuated virus (PLLAV) platform. AstriVax has received a €2.5
Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.
The ways in which we communicate and consume information are constantly transforming. In 2020, the challenges of the COVID-19 pandemic greatly accelerated the pace of this evolution, with wide-reaching effects on many aspects of medical communications. Q1: What are some ways in which data dissemination has evolved in 2020?
According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK.
Since the first human administration of the Bacillus Calmette-Guérin vaccine in 1921, no one has been able to successfully follow the vaccine’s path to become the next approved vaccine to tackle tuberculosis (TB). However, as the TB-related death toll remains high, the global need for another vaccine is steadily rising.
Each year we look back to take stock of how the agency has been communicating in the course of the previous year and assess how that might compare to years gone by. When Dr. Scott Gottlieb took the reins of FDA as Commissioner, the amount of communications material put out jumped enormously. When will the products be fully approved?
After a long period of inactivity in RSV vaccine development , two pharmaceutical companies are now approaching regulatory decisions for their RSV vaccines. Both Pfizer and GSK have major approval decisions regarding the use of their RSV vaccines for older adults this May. What incentivises a country to cover a vaccine?
RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. This is a significant increase compared to the 2021–20 season when the rate was 28.3 According to the Centers for Disease Control and Prevention (CDC) , 45.8
But here is what we see looking at the first 6 months 2021, and comparing it to mid-years past. As we saw with the “Gottlieb effect”, Commissioners can make a difference in the agency’s approach to communications. Of the 153, only 33 of them were translated into Spanish. We’ll check in again at year end.
Pharma marketers have quickly learned how to adapt to these trends and are prepared to take on new opportunities in 2021. Trend #1: Media and Tech: Facilitating Communication. Tools that help people track their health, including apps, wearables, and patient portals will be used more than ever in 2021.
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
As COVID-19 vaccines are hastily deployed in the UK for priority groups, a debate rages over the government’s controversial strategy to delay time between vaccine doses. When the UK announced the approval of the Pfizer-BioNTech and Oxford/AstraZeneca COVID-19 vaccines, it marked an exciting moment for the nation.
Food and Drug Administration (FDA) announced its approval of the Boostrix vaccine, commonly known as Tdap (combination of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis) for immunization administration during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.
People can opt out of the scheme by filling in a form and taking it to their GP before 23 June, but campaigners say this has not been communicated effectively. — Foxglove (@Foxglovelegal) May 26, 2021. For news on this case, sign up here: [link].
Towards the conclusion of 2021 many societies announced another shift in format; 2022 conferences would be hybrid, or increasingly and more realistically described as ‘physical with virtual participation options,’ or similar. This article summarises the most important lessons learnt during 2020 – 2021. Lessons learnt 2020-2021.
Germany has decided that AstraZeneca’s COVID-19 vaccine should be approved for use in the over-65s after all, reversing its earlier restriction in that age group. . — Jens Spahn (@jensspahn) March 4, 2021. France has said the vaccine can be used in people aged up to 74, rather than the entire over 65s age group.
Supply chain challenges take many forms in pharma – from capacity issues, to managing excess safety stock, and ensuring accurate supplier communication. Better communication with traceable data. Automated systems allow suppliers to maintain complete traceability over their processes and communicate in the most effective way possible.
In 2021, a CISCRIP Perceptions and Insights Study reported more disruption to daily routines compared to previous years, citing length of visits, travel, and diagnostic tests as top burdens. Cloud platforms can open two-way communication channels for patients, doctors, and trial administrators to talk and share data, essentially in real-time.
This method not only prioritizes the participant’s comprehension but also aligns with best practices in health communication that suggests a focused approach can significantly enhance understanding and retention of important information. The importance of using plain language in health communications is well-documented in literature.
Not only has COVID forced companies, governments and healthcare systems to work towards approving drugs and vaccines in record times, the sector is also facing an influx of digital therapeutics and advanced drugs that don’t fit neatly into existing access frameworks. How to improve payer engagement with tailored value communication.
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.
That’s according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), which has detailed the organisation’s 2021 Connecting Healthcare Awards winners in its fourth annual Health Collaboration Guide. About the author. Amanda Barrell is a freelance health and medical education journalist, editor and copywriter.
In a recent blog posting, I looked back at the profile of FDA press releases over the period 2013-2021 (See What They Said 2021 – An Overview of FDA Press Statements ). In it we saw that FDA had a good deal to say in 2020 putting out over 400 press statements, but that output fell considerably in 2021.
Ahead of the World IVF Day, Bharat Serums and Vaccines (BSV) has roped in Bureau Veritas (India), as part of the BSV ART Act Readiness Program. On the occasion of World IVF Day, as responsible leaders in IVF treatment, we are delighted to announce a first-of-its-kind initiative from BSV – ‘The ART Act Readiness Assessment Program’.
Since 2021, pharmacy-related organizations have been addressing stress and burnout in the profession. The stress experienced by community pharmacists compared to those in other settings is well-documented and has been a longstanding issue. Despite this report being from 2021, the issue still hasn’t been resolved.
Pharmaron is receiving a £151 million investment in capital to support the growth of operations in Liverpool, quadrupling production capacity for gene therapy and vaccine components. 2021 was a year of continued innovation and change in the Biopharmaceutical industry. Free Report How is the Biopharmaceutical industry evolving?
While trials of COVID-19 vaccines and treatments have accelerated at a hitherto unimaginable rate, work in other conditions has been halted and paused, both of which could hinder future progress, said Aisling Burnand, chief executive of the Association of Medical Research Charities (AMRC). Weaknesses.
of the draft revised Community Code provides a reduction in the basic data exclusivity period for innovative medicinal products from eight to six years, a revision which did not come as a great surprise to many. As an example, Article 81.1 The European Commission has evidently expended significant effort in developing the proposals.
billion ($103 billion) set for 2021–27. 2021 was a year of continued innovation and change in the Biopharmaceutical industry. If the Horizon Europe negotiations do not pan out, the UK plans to push the Pioneer program, for which it would invest roughly £14.6 billion ($18.2 billion) by 2030. Horizon Europe has a budget of €95.5
According to a 2021 survey, 1/3 of Americans take on additional roles outside of their full-time jobs. This role is great for helping you enhance your communication skills. Telehealth nursing helps you become a better communicator with all types of patients and professionals. Average pay: $125-$200 per hour 3. per hour 10.
Among other things, supply chain optimisation, maintaining access to affordable vaccines, and supporting innovation for unmet clinical needs will be the discussion topics, she adds. 2021 was a year of continued innovation and change in the Biopharmaceutical industry. Free Report How is the Biopharmaceutical industry evolving?
For the pharma supply chain in particular, 2020 and 2021 were boom years in terms of investment. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg. GlobalData analysis shows virtual trials increased 50% year on year between 2020 and 2021. Source: GlobalData.
Many pharmacists can now administer diagnostic tests and vaccines, as well as dispense treatments for coronavirus disease 2019 (COVID-19). Telehealth capabilities were also expanded, allowing patients in rural or underserved communities to access pharmacist care. Updates will be posted on the NABP website and other communications.
In 2020 and 2021, we saw pharma forced to become more flexible and open-minded than ever before. This is likely something we will be living with until we crack the code on how to vaccinate the unvaccinated, and even then we’re all likely to be getting boosters for a long-time. In this article, R.J. Innovation & Experimentation.
This year is a telling one and FDA may be changing the nature of the way they are communicating with the public. Not only was there less activity in relation to the COVID emergency, but we have had a change in leadership at FDA, which can have a big impact on how the agency communications. There may be several factors at play.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content